Exagen: The Path To Profitability Just Became More Credible

Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis.

XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers.

Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity.

Despite a 38% post-earnings rally, I maintain a Buy rating, targeting 62% upside by 2028 as the business' fundamental improvements gain market recognition.

Exagen ( XGN ) delivered a quarter that strengthened my conviction in the turnaround story.

Revenue growth remained in the mid-teens, average selling prices reached another record, operating This article was written by Fernanda Galvez Jalil 1.18K Followers Follow My name is María Fernanda and I'm currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, so I look to predict what a business's earnings per share will do.